CIDP
Clinical trials for CIDP explained in plain language.
Never miss a new study
Get alerted when new CIDP trials appear
Sign up with your email to follow new studies for CIDP, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New treatment option opens for CIDP patients who have no other choices
Disease control AVAILABLEThis program provides efgartigimod PH20 SC to adults with CIDP who cannot join a clinical trial and have not gotten better with standard treatments like steroids or immunoglobulins. The goal is to offer a potential treatment option for those with active disease and unmet medical …
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
New study tracks Real-Life impact of CIDP drug on 200 patients
Disease control Recruiting nowThis study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over two years to see how well the drug works in real…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 05:07 UTC
-
New hope for CIDP: blood filtering vs. standard antibody therapy in Head-to-Head trial
Disease control Recruiting nowThis study tests if a blood-filtering method (immunoadsorption) works as well as standard antibody infusions (immunoglobulins) for people with CIDP, a nerve disorder causing weakness and numbness. It includes 20 adults with CIDP who did not improve with steroids. The goal is to s…
Matched conditions: CIDP
Phase: PHASE2 • Sponsor: University of Ulm • Aim: Disease control
Last updated May 17, 2026 05:06 UTC
-
New CIDP drug shows promise in Head-to-Head trial against standard care
Disease control Recruiting nowThis study compares a new intravenous drug, empasiprubart, to standard intravenous immunoglobulin (IVIg) in 218 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants first receive either empasiprubart or…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New CIDP drug trial offers hope for nerve damage relief
Disease control Recruiting nowThis study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Body shape may change how drug works for nerve disease
Knowledge-focused Recruiting nowThis study looks at whether a person's body composition (like muscle and fat) changes how immunoglobulin G (IgG) is processed after IV or under-the-skin injections. Researchers will measure drug levels and half-life in 20 adults with CIDP, a nerve condition. The goal is to improv…
Matched conditions: CIDP
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 14, 2026 12:01 UTC